EDAP$3.59
Chart
Performance
Key Stats
AI EDAP Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldEDAP TMS S.A. demonstrates potential in its niche market, but faces significant financial challenges and a highly negative short-term outlook. Investors should exercise caution.
Thematic
EDAP TMS operates in the growing medical device sector, specifically focusing on minimally invasive urology solutions. Advancements in prostate cancer treatment and the increasing demand for non-invasive procedures are positive thematic drivers.
Fundamental
EDAP TMS is experiencing significant revenue decline and persistent net losses, with a concerning cash burn rate. While the balance sheet has adequate cash, the profitability and growth metrics are negative.
Technical
The stock is in a strong downtrend, trading below key moving averages and showing weak momentum indicators. Immediate price action suggests further downside risk.
| Factor | Score |
|---|---|
| Medical Device Innovation | 80 |
| Healthcare Sector Growth | 70 |
| Aging Population & Chronic Diseases | 85 |
| Regulatory Landscape (Healthcare) | 75 |
| Market Competition | 65 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 10 |
| Growth | 15 |
| Balance Sheet Health | 60 |
| Cash Flow | 10 |
| Debt Level | 70 |
| Factor | Score |
|---|---|
| Trend Analysis | 20 |
| Momentum | 40 |
| Price Performance (1Y) | 10 |
| Volume | 50 |
| Support & Resistance | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
Improving EPS Trend
While recent EPS has been negative, the trend shows increasing estimates (e.g., Q1 2025 estimate of -0.10 vs. prior negative quarters) and some positive surprises (Q1 2025 reported EPS of -0.05 exceeded estimate). This suggests potential stabilization and recovery.
Strong Cash Position
The company has significant cash and cash equivalents (e.g., $29.8M in Q4 2024), which provides a cushion for operations and investments, especially given recent negative free cash flow.
Bearish Points (7)
Consistent Net Losses
The company has consistently reported negative net income and negative EPS (e.g., -19.0M net income in 2024, EPS of -0.68 TTM). This indicates ongoing profitability challenges.
Negative Free Cash Flow
The company has demonstrated negative free cash flow for multiple periods (e.g., -17.7M in 2024, -19.0M in 2023). This trend, coupled with negative operating cash flow in recent quarters, indicates cash burn and potential need for financing.
Calendar
August 2025
27
Next Earnings Date
H: $-0.16
A: $-0.16
L: $-0.17
H: 17.28M
A: 16.60M
L: 15.80M
Profile
EDAP TMS S.A., together with its subsidiaries, develops, manufactures, promotes, and distributes minimally-invasive medical devices for urology based upon proprietary ultrasound technology in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution segments. The HIFU segment develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. This segment also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL segment manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters. This segment also sells spare parts and disposables, such as electrodes. The Distribution segment markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing and sales channels, as well as through third-party distributors and agents. The company serves academic, public, and private hospitals as well as urology clinics. EDAP TMS S.A. was incorporated in 1979 and is based in Vaulx-en-Velin, France.
Seasonals
Price Target
5.75 USD
The 39 analysts offering 1 year price forecasts for EDAP have a max estimate of 14.00 and a min estimate of 1.50.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Direct competitor in non-invasive prostate treatment with TULSA-PRO (MRI-guided focused ultrasound), addressing similar patient needs as EDAP's HIFU technology.
Weight: 95
Dominant in robotic-assisted surgery (da Vinci), which is a major alternative surgical treatment for prostate cancer (prostatectomy), often considered alongside EDAP's less invasive options.
Weight: 92
Developing histotripsy (non-thermal mechanical ultrasound ablation), a potentially competitive or complementary technology to HIFU for precise tissue destruction in oncology.
Weight: 90
Provider of radiation therapy systems (CyberKnife, TomoTherapy) for cancer, including prostate cancer, offering an alternative treatment modality to HIFU.